

increments) to define a maximum non-toxic metronomic dose (MNMD). In phase-beta, patients allocated randomly to one of three dose levels (low-medium-MNMD) and underwent blood sampling throughout the treatment to analyze for kinetics of surrogate biomarkers of angiogenesis (soluble VEGF, VEGFR2, TSP1, bFGF and circulating progenitor endothelial cells) and twice for pharmacokinetics. OMD will be defined by considering kinetic profile of biomarkers in association with antitumor activity and pharmacokinetics.

**Results:** Forty six patients [21 female and 25 male; median age 58 range 38–85 years; median PS 1, median prior treatments 2 range 0–7] were enrolled between June 2004 and May 2005. They had a variety of progressive refractory solid cancers and were treated at the dose range of 20 to 50 mg. All patients received continuous non-stop therapy without overt clinical toxicity. Median time of treatment failure was 17 weeks (range 6 to 44+ weeks) that also corresponded to time to progression, since no withdrawals from therapy were due to toxicity. MNMD has not been reached and dose is presently escalated to 60 mg. Objective tumor response (confirmed partial remission) was documented in four cases (renal cancer, NSCLC, unknown primary and sarcoma Kaposi) and 32% of treated patients had stable disease for more than 6 smonths. The trial is ongoing to define the OMD.

**Conclusions:** Continuous administration of metronomic oral vinorelbine, given TIW is feasible and exceptionally well tolerated at doses up to 50 mg. Early results show activity against refractory tumors and provide evidence towards clinical proof of principle for metronomic chemotherapy. Data on biomarker analysis and pharmacokinetics will be presented at the meeting.

## 1461

## POSTER

### Circulating endothelial cells and monocytes as markers of sunitinib malate (SU11248) activity in patients with imatinib mesylate-resistant GIST

A. Norden-Zfoni<sup>1</sup>, J. Manola<sup>2</sup>, J. Desai<sup>2</sup>, J. Morgan<sup>2</sup>, C. Bello<sup>3</sup>, S. DePrimo<sup>3</sup>, D. Shalinsky<sup>3</sup>, C. Baum<sup>3</sup>, G. Demetri<sup>2</sup>, J. Heymach<sup>2</sup>.

<sup>1</sup>Children's Hospital, Boston, USA; <sup>2</sup>Dana Farber Cancer Institute, Boston, USA; <sup>3</sup>Pfizer Global R&D, La Jolla, USA

**Background:** This study evaluated circulating endothelial cells (CECs), monocytes (MCs), circulating VEGF and soluble VEGFR-2 (sVEGFR-2) as potential pharmacodynamic markers of sunitinib malate (SU) activity in GIST patients (pts).

**Materials and methods:** SU is an oral multitargeted tyrosine kinase inhibitor of VEGFR, PDGFR, KIT, RET and FLT3 with antiangiogenic and antitumor activities. The majority of pts enrolled in a phase I/II trial of SU for metastatic GIST resistant to imatinib mesylate (IM) therapy received repeating cycles of 50 mg SU daily for 4 wks followed by 2 wks off treatment. CBC and differential WBC counts were taken pre- and post-treatment in 73 pts enrolled in the study. In 16 pts, CECs were assessed serially by 4-color flow cytometry. Changes in mature CEC and MC counts were correlated with clinical outcome, classified as either clinical benefit (CB: PFS >6 mos) or PD. Plasma levels of soluble proteins were analyzed using validated sandwich ELISA assays.

**Results:** MC levels decreased 54% after 2 wks of SU therapy ( $P < 0.001$ ) and rebounded (96%) after 2 wks off therapy ( $P < 0.001$ ). This pattern of decrease and increase in MC levels during periods on and off SU therapy was observed across multiple drug cycles, while no such pattern was observed with lymphocytes. After 2 wks of SU therapy, mean MC count decreased 59% in the PD group, but only 48% in the CB group ( $P = 0.03$ ). CEC counts increased significantly early after initiation of SU therapy (first follow-up: 6–20 d), but not at subsequent timepoints. Changes in CEC count following therapy distinguished pts based on clinical outcome: all 7 pts with SU-related CB also exhibited a rise in CEC count between baseline and first follow-up, while only 3 of 9 pts with PD had a rise in CEC count. The rate of change per day in CECs was significantly different between pts with CB and PD (median: 0.52 vs. -0.01 cells/ $\mu$ L;  $P = 0.03$ ). After active treatment in each cycle, mean plasma VEGF levels increased by an average of 2.9-fold, while mean sVEGFR-2 levels decreased by an average of 1.7-fold, with both returning to near-baseline levels during treatment breaks. These changes did not strongly correlate with clinical outcome.

**Conclusions:** Percent drop in MC counts and rate of change per day in mature CECs distinguished pts with metastatic IM-resistant GIST who experienced CB during SU therapy from those who did not. CEC and MC counts may be useful markers for identifying pts who may ultimately benefit from SU therapy.

## 1462

## POSTER

### A multicenter Phase II trial of gefitinib 500 mg/day in 192 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy.

I. Vergote<sup>1</sup>, Y. Humblet<sup>2</sup>, E. Van Cutsem<sup>1</sup>, S. Van Belle<sup>3</sup>, J. Kerger<sup>4</sup>, J. Van Laethem<sup>5</sup>, J. Canon<sup>6</sup>, F. Forget<sup>7</sup>, F. Amant<sup>1</sup>, A. Van Oosterom<sup>1</sup>.

<sup>1</sup>University Hospitals Leuven, Division of Obstetrics and Gynaecology, Department of Gynaecologic Oncology, Leuven, Belgium; <sup>2</sup>UCL Saint-Luc Bruxelles, Department of Medical Oncology, Brussels, Belgium; <sup>3</sup>University Hospitals Ghent, Department of Medical Oncology, Ghent, Belgium; <sup>4</sup>Cliniques Universitaires de Mont-Godinne, Department of Medical Oncology, Yvoir, Belgium; <sup>5</sup>Hôpital Erasme Bruxelles, Division of Digestive Oncology, Department of Gastro-Enterology, Brussels, Belgium; <sup>6</sup>Centre Hospitalier Notre-Dame et Reine Fabiola, Department of Medical Oncology, Charleroi, Belgium; <sup>7</sup>Centre Hôpital de l'Ardenne, Department of Medical Oncology, Libramont, Belgium

**Background:** 15 Belgian oncology centers participated in an open-label Phase II trial of gefitinib (IRESSA) 500 mg/day in patients (pts) with advanced epidermal growth factor receptor-positive solid tumors who had failed >1 previous chemotherapy regimen and had no further chemotherapy treatment options.

**Methods:** EGFR expression was assessed using DakoCytomation's EGFR pharmDx<sup>TM</sup> kit. Pts with EGFR expression of >1 received gefitinib 500 mg/day until disease progression. Objective tumor assessments, by RECIST, were made every 8 weeks and confirmed by repeat assessments >4 weeks later. Disease control rate (DCR) was defined as objective response (confirmed complete response or partial response [PR]) plus stable disease (SD) for >8 weeks. All adverse events (AEs) were reported and assessed by NCI-CTC version 2.0.

**Results:** 192 pts have been enrolled with the following tumors: pancreatic cancer (PC) [n = 39], cervical cancer (CC) [n = 36], ovarian cancer (OC) [n = 33], sarcoma (S) [n = 23], cancer of unknown primary origin (U) [n = 19], hepatocellular carcinoma (HC) [n = 18], bladder cancer (BC) [n = 14], and endometrial cancer (EC) [n = 10]. Mean time between first tumor diagnosis and the start of gefitinib treatment was 33.5 months ( $\pm 44.8$ ). 18 pts (HC only) had received no previous chemotherapy, 74 pts 1 line, 58 pts 2 lines and 42 pts >3 lines. DCR was 34%: 7 pts had a PR (3 CC, 3 OC, 1 PC) and 58 pts had SD at 8 weeks (16 CC, 9 OC, 8 S, 6 PC, 9 HC, 4 EC, 3 BC, 3 U). Mean duration of disease control was 27.2 weeks ( $\pm 2.2$ ). 84% of pts had at least one drug-related AE. In 16% of patients (n = 31), this drug-related AE was CTC grade 3, in 0.5% (n = 1) of patients CTC grade 4. Most of these grade 3–4 adverse events were of cutaneous or gastrointestinal origin. Gefitinib dose reduction to 250 mg/day was required in 21% of pts. In 7% of patients gefitinib treatment was withdrawn because of drug-related AEs.

**Conclusions:** Gefitinib showed promising activity and acceptable tolerability in patients with EGFR-positive pancreatic cancer, cervical cancer and ovarian cancer. Our data support findings from previous gefitinib Phase I/II trials in patients with advanced cervical cancer<sup>1</sup> and ovarian cancer [2]. IRESSA is a trademark of the AstraZeneca group of companies

## References

- [1] Viens et al. ASCO 2003; abstract 1833.
- [2] Ranson et al. J Clin Oncol 2002;20:2240–50.

## 1463

## POSTER

### The urinary excretion of L-carnitine and its short-chain ester acetyl-L-carnitine in patients undergoing carboplatin treatment

A. Mancinelli<sup>1</sup>, S. D'Iddio<sup>1</sup>, R. Bisonni<sup>2</sup>, F. Graziano<sup>3</sup>, P. Lippe<sup>4</sup>, M. Calvani<sup>1</sup>. <sup>1</sup>Sigma-Tau, Scientific Department, Pomezia (Rome), Italy; <sup>2</sup>Medical Oncology Unit, Hospital of Fermo, Fermo, Italy; <sup>3</sup>Medical Oncology Unit, Hospital of Urbino, Urbino, Italy; <sup>4</sup>Medical Oncology Unit, Hospital of Fano, Fano, Italy

**Background:** During chemo- and radio-therapy cancer patients experience fatigue symptoms. Dietary and nutritional factors are among postulated to be involved in the multifactorial aetiology of fatigue. In fact, when L-carnitine (LC), a compound necessary for energy production through mitochondrial fatty acid oxidation, is reduced in the body or its endogenous system is altered, fatigue symptoms appear and are improved after its administration. Some anticancer drugs, such as cisplatin, cause excessive urinary LC elimination through a possible inhibition of its renal reabsorption. Other platinum-derivatives, such as carboplatin, could have a similar effect. This study investigated the influence of carboplatin treatment on plasma concentration and urinary excretion of LC and its main ester, acetyl-L-carnitine (ALC) in tumoral patients.